Impotence, Arteriogenic Clinical Trial
Official title:
Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients With Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB)
In this prospective, unblinded, single-arm, single-center study, investigators would like to assess the feasibility and safety of the bioabsorbable everolimus-eluting stents in patients with erectile dysfunction and concomitant internal pudendal artery stenoses. A total of 15 bioabsorbable vascular scaffolds (BVSs) are planned to be assessed and will be deployed in the internal pudendal artery, with a 1:1 ratio of both proximal and distal segments.
Status | Not yet recruiting |
Enrollment | 15 |
Est. completion date | March 2017 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - men 20 years of age or older with "consistent" erectile dysfunction defined as both IIEF-5 scores, taken at least 4 weeks apart, are in the range of 5 to 21 points and with a difference of =2 points; - the anatomical inclusion criteria, based on pelvic CT angiography, are unilateral luminal diameter stenosis =70% or bilateral diameter stenoses =50% in the internal pudendal arteries with reference vessel diameter =2.5 mm and =4.0 mm and a target-lesion length =30 mm. Exclusion Criteria: - the arterial inflow to the penis is entirely from the accessory pudendal arteries rather than the usual internal pudendal artery and common penile artery; - the presence of focal diameter stenosis =70% in the common penile artery, internal iliac artery, or anterior division of inferior gluteal artery; - previous radical prostatectomy, pelvic radiation, or Peyronie's disease; - untreated hypogonadism (serum total testosterone <300 ng/dL within 14 days before enrollment); - acute coronary syndrome, stroke, or life-threatening arrhythmia within 3 months before enrollment; - poorly controlled diabetes mellitus with glycosylated hemoglobin levels >9%; - serum creatinine levels >2.5 mg/dL; - bleeding diathesis or known hypercoagulopathy; - life expectancy of fewer than 12 months; - known intolerance to contrast agents. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital | Abbott |
Wang TD, Lee WJ, Yang SC, Lin PC, Tai HC, Hsieh JT, Liu SP, Huang CH, Chen WJ, Chen MF. Safety and six-month durability of angioplasty for isolated penile artery stenoses in patients with erectile dysfunction: a first-in-man study. EuroIntervention. 2014 May;10(1):147-56. doi: 10.4244/EIJV10I1A23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CT angiographic binary restenosis | Binary restenosis is defined as >=50% lumen diameter stenosis | 6 months | No |
Secondary | Diameter measured by invasive angiography | Diameter will be measured by invasive angiography at in-stent, peri-stent, and in-segment sections | 6-9 months | No |
Secondary | Diameter stenosis measured by invasive angiography | Diameter stenosis will be measured by invasive angiography at in-stent, peri-stent, and in-segment sections | 6-9 months | No |
Secondary | Late loss measured by invasive angiography | Late loss will be measured by invasive angiography at in-stent, peri-stent, and in-segment sections | 6-9 months | No |
Secondary | International Index of Erectile Function (IIEF)-5 score | 1, 3, 6, and 12 months | No | |
Secondary | Major adverse events | Major adverse events are defined as procedure-related death, occurrence of perineal hematoma, gangrene or necrosis (glans penis, penile shaft, scrotal, or anal), or the need for subsequent perineal, penile, or anal surgery (including target-lesion or vessel revascularization or arterial embolization procedures). | 1, 3, 6, and 12 months | Yes |